Natera Inc Stock Price, News & Analysis

Natera, a leader in cell-free DNA testing, will release its Q1 2022 financial results on May 5, 2022, after market close. A conference call will follow at 1:30 PM PT to discuss these results and future outlook. The company's operations span oncology, women's health, and organ health, supported by over 100 peer-reviewed studies affirming their test accuracy. Natera is committed to integrating personalized genetic testing into standard care, thereby enhancing patient health.

Natera, Inc. (NASDAQ: NTRA) announced the RenaCARE study, aiming to assess the clinical utility of its Renasight genetic testing panel for chronic kidney disease (CKD). The study is projected to enroll 2,000 patients by Q2 2022, building on previous research showing that 89% of patients with positive multi-gene tests had actionable clinical implications. With 1,600 patients enrolled across 25 sites, the study will evaluate the impact of genetic findings on patient care management, satisfaction, and genetic literacy, contributing to evidence on the value of genetic testing in CKD.

Natera, Inc. (NASDAQ: NTRA) announced findings from a significant real-world study demonstrating a 21.1% positive yield for genetic findings using its Renasight™ test in chronic kidney disease (CKD) patients. Out of 1,007 patient samples analyzed, 220 positive results were identified across 48 genes, underscoring Renasight's effectiveness for genetic diagnoses in nephrology. The study highlights Renasight's potential to aid in clinical management and inform treatment options for the approximately 37 million U.S. adults affected by CKD.

Natera, Inc. (NASDAQ: NTRA) announced the publication of its DEDUCE study in the Journal of Heart and Lung Transplantation, demonstrating the effectiveness of its Prospera™ Heart test in assessing acute rejection in heart transplant patients. The study analyzed 703 prospective samples, achieving an impressive AUC of 0.86. The test shows potential to replace invasive biopsies and is backed by further trials, including NIH-supported studies anticipated to involve over 775 patients. This advancement highlights Natera's commitment to precision in heart transplant care.

Natera, Inc. (NASDAQ: NTRA) announced new findings regarding its Signatera personalized molecular residual disease test at the American Association for Cancer Research annual meeting held from April 8-13, 2022. The data focuses on triple negative breast cancer (TNBC) and high-risk hormone receptor-positive/HER2-negative patients. Key results include a significant correlation between detectable circulating tumor DNA (ctDNA) post-surgery and poor outcomes, with a lead time of up to 30 months before recurrence. This reinforces Signatera's role in enhancing patient management for breast cancer.

Natera, Inc. (NASDAQ: NTRA) announced the publication of the VALID study, validating its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test for assessing lung transplant rejection. The study analyzed 195 biopsy-matched samples, demonstrating the test's robust performance, with a 0.91 AUC for acute rejection against stable cases. Already in use at 25% of U.S. lung transplant centers, the Prospera test promises improved patient outcomes in lung transplantation. The study was published in Transplant Direct.

Natera, Inc. (NASDAQ: NTRA) announced the appointment of Sangeeta Bhorade, M.D., as the new vice president of organ health medical affairs.

Dr. Bhorade brings over 27 years of experience, including her role at the University of Chicago and Northwestern University. This addition follows other key hires, enhancing Natera's leadership in organ health. Her expertise is expected to drive innovation and improve patient care. With this new leadership, Natera aims to strengthen its position in the organ health sector.

Natera, Inc. (NASDAQ: NTRA) announced a study published in Transplantation Proceedings that highlights the significance of total cell-free DNA (cfDNA) testing in kidney transplant recipients hospitalized with COVID-19. Using its Prospera™ test, the study reveals that elevated total cfDNA can obscure donor-derived cfDNA (dd-cfDNA) levels, potentially masking transplant rejection cases. The Prospera test identified two patients whose biopsy-proven rejections were undetected by dd-cfDNA alone. This research underscores the necessity of total cfDNA in understanding graft health amidst COVID-19 challenges.

Natera, a leader in cell-free DNA testing, has been recognized by Fast Company in its annual list of the World's Most Innovative Companies for 2022. The company ranked sixth in the Health category, acknowledged for its Signatera™ MRD test, which effectively monitors therapy response and predicts patient benefit from immunotherapy across various cancer types. This recognition highlights the test's significant impact, particularly after Medicare's approval for its serial use in pan-cancer immunotherapy monitoring.